<DOC>
	<DOCNO>NCT02108145</DOCNO>
	<brief_summary>Cholangiocarcinoma ( CCA ) common biliary malignancy second common hepatic malignancy hepatocellular carcinoma ( HCC ) . A majority CCA ( 50-70 % ) present area biliary duct bifurcation . Recent retrospective study include heterogeneous group malignant diseases demonstrate drain 50 % associate long median survival . However , recent European Society Gastrointestinal Endoscopy ( ESGE ) biliary stenting clinical guideline Asia-Pacific consensus recommendation endoscopic interventional management hilar cholangiocarcinoma ( HCCA ) , whether deployment bilateral unilateral metal stent patient HCCA clearly recommend due absence randomize controlled trial .</brief_summary>
	<brief_title>Percutaneous Bilateral Versus Unilateral Metal Stent Hilar Cholangiocarcinoma</brief_title>
	<detailed_description>Patients advance hilar obstruction ( Bismuth III IV ) , PTBS high success rate cholestasis palliation low rate post cholangitis compare endoscopic retrograde cholangiopancreatography ( ERCP ) . The advantage percutaneous approach precise lobar selection drainage approach yield lower rate cholangitis . Guideline recommendation European Society Gastrointestinal Endoscopy ( ESGE ) biliary stenting clinical guideline Asia-Pacific consensus recommendation goal palliative stenting HCCA drainage adequate liver volume ( 50 % ) , irrespective unilateral , bilateral , multi-segmental stenting base heterogeneous group malignancy ERCP retrospective study.There randomize clinical trial compare two internal biliary drainage method HCCA use metal stent . The aim present study compare effect safety bilateral versus unilateral stenting patient HCCA .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Klatskin Tumor</mesh_term>
	<criteria>Written inform consent ; Jaundice duo biliary obstruction ; The diagnosis base typical feature MRI magnetic resonance cholangiopancreatography histologic cytologic confirmation establish percutaneous biopsy ( X rayguided ) exploratory laparotomy ; Bismuth type Ⅱ、Ⅲ、Ⅳobstruction ; Performance status ( eastern cooperative oncology group , ECOG ) 02 ; All patient consider unsuitable refuse resection basis general medical condition and/or tumor extent . Refuse participate provide informed consent ; Bismuth Ⅰtype obstruction ; Performance status ( eastern cooperative oncology group , ECOG ) 34 . Portal Vein involvement ; Prior history stent ; Concomitant renal insufficiency ; Severe cardiopulmonary disease ; Uncontrolled systemic infection sepsis ; Accompany malignancy serious medical illness may reduce life expectancy . Contraindications PTBS .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>cholangiocarcinoma</keyword>
	<keyword>jaundice</keyword>
	<keyword>metal stent</keyword>
	<keyword>PTBS</keyword>
</DOC>